Jim Cramer says he likes Corteva and Nucor for 2023

Jim Cramer says he likes Corteva and Nucor for 2023


Cramer explains what the trajectory of stocks in the materials sector this year reveals about Wall Street

CNBC’s Jim Cramer on Monday offered investors two stocks they should consider adding to their portfolios.

Stocks in the materials sector tend to be highly cyclical, meaning they could get hammered if the Federal Reserve’s interest rate hikes tip the economy into a recession, he explained. 

And while it’s far from the best-performing sector in the S&P 500, “even the weakest of these groups have some winners that managed to buck the overall trend and it’s important to figure out if they can keep doing what they did [this year] in 2023,” Cramer said.

Here are his thoughts on his two stock picks:

Corteva

Cramer recommended that investors buy the seeds and agricultural chemical company stock on its next pullback. He reasons that strong crop prices this year have left farmers flush with cash and more likely to invest in efficient farming.

“Plus, even though the stock’s up 23% for the year, it still sells for less than 19 times next year’s earnings estimates — far from expensive,” he said.

Nucor

Calling Nucor the “best steelmaker in America,” he said that he’s certain its stock will have an up year in 2023 after it flexed its ability to continue posting solid earnings results despite the Federal Reserve’s tightening. The company will also be a huge beneficiary of the over $1 trillion bipartisan infrastructure bill, Cramer predicted. Shares of Nucor are up over 15% year to date.

“Remember, a year ago the analysts thought Nucor could only make $16 in 2022 and they ended up trouncing those estimates. I wouldn’t be surprised if they put on a repeat performance,” he said.

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More